Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: chimeric antigen receptor T cell therapeutics - Atossa Therapeutics

Next Previous
Drug Profile

Research programme: chimeric antigen receptor T cell therapeutics - Atossa Therapeutics

Alternative Names: TRAP CAR-T - Atossa Therapeutics

Latest Information Update: 28 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Atossa Genetics
  • Developer Atossa Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Breast cancer

Highest Development Phases

  • No development reported Breast cancer

Most Recent Events

  • 28 Aug 2022 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
  • 18 Jul 2018 Preclinical trials in Breast cancer in USA (Parenteral)
  • 28 Dec 2017 Atossa Genetics plans to initiate studies administering TRAP CAR-T cell with microcatheters for Breast cancer in the second half of 2018
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top